NMN
Also known as: Nicotinamide Mononucleotide · Beta-NMN
A direct NAD+ precursor that restores declining NAD+ levels with age. Strong mechanistic data, growing human trial evidence.
Mechanism of Action
Converts to NAD+ via the Preiss-Handler pathway. NAD+ is essential for sirtuins, PARP DNA repair, and mitochondrial energy production.
Doses and timing reported in studies
Context, not a recommendation. Study links for this card are still being added, so check the original trials and talk to your doctor before you take anything, especially with medicines or health conditions.
Range used in trials
250–500mg/day
Timing used in trials
Morning with or without food
Stacks Well With
Rubric
How evidence grades work
A grade summarises the strength of the human evidence for a compound or device category. It is not a score, it is not a rating of any brand, and it changes when new studies land.
- Strong
- Several randomised controlled trials or meta-analyses in people agree on direction, the effect is large enough to matter for the stated outcome, and safety is established over long use.
- Moderate
- Some human trials, but small, short, or mixed. Plausible benefit, with limited long-term safety data.
- Emerging
- Mostly animal or mechanism studies, or very small human studies. Interesting, not yet enough to act on.
- Weak
- Little or contradictory evidence, no benefit shown, or a safety concern outweighs the evidence.